First-in-Human Positron Emission Tomography Study Using the 18F-?v?6-Binding-Peptide
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Breast Carcinoma
- Colorectal Carcinoma
- Lung Carcinoma
- Metastatic Malignant Neoplasm in the Breast
- Metastatic Malignant Neoplasm in the Colon
- Metastatic Malignant Neoplasm in the Lung
- Metastatic Malignant Neoplasm in the Rectum
- Pancreatic Carcinoma
- Type
- Interventional
- Phase
- Early Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
PRIMARY OBJECTIVES: I. To determine the safety, biodistribution and dosimetric properties of 18F-alphavbeta6-binding peptide (BP) in normal tissues and malignancies in cancer patients and correlate concordance with alphavbeta6 expression. OUTLINE: Patients receive 18F-alphavbeta6-BP intravenously (I...
PRIMARY OBJECTIVES: I. To determine the safety, biodistribution and dosimetric properties of 18F-alphavbeta6-binding peptide (BP) in normal tissues and malignancies in cancer patients and correlate concordance with alphavbeta6 expression. OUTLINE: Patients receive 18F-alphavbeta6-BP intravenously (IV) and then undergo positron emission tomography (PET) scans over 30 minutes each at 30, 60, 120, and 180 minutes post-injection. After completion of study, patients are followed up for up to 6 months.
Tracking Information
- NCT #
- NCT03164486
- Collaborators
- National Cancer Institute (NCI)
- Investigators
- Principal Investigator: Julie Sutcliffe University of California, Davis
Get Well Soon